Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6040996 | 0.84 | — | — | |
| SCHEMBL4256819 | 0.83 | MAPT (0.43) | MAPTGAAMMP1MMP3MMP8 | |
| SCHEMBL28237924 | 0.79 | MAPT (0.41) | MAPTGAAMMP1MMP3MMP8 | |
| SCHEMBL1246279 | 0.79 | MMP1 (0.46) | MAPTGAAMMP1MMP3MMP8 | |
| SCHEMBL10931251 | 0.78 | DPP4 (0.33) | SMN1; SMN2 | |
| SCHEMBL6041079 | 0.78 | — | — | |
| SCHEMBL1276983 | 0.77 | MAPT (0.46) | MAPTGAAMMP1MMP3MMP8 | |
| SCHEMBL11531391 | 0.74 | MAPT (0.45) | MAPTGAAMMP1MMP3MMP8 | |
| SCHEMBL29727668 | 0.74 | MAPT (0.45) | MAPTGAAMMP1MMP3MMP8 | |
| SCHEMBL6040966 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116370491-A | Use of antisense oligonucleotides in treating coronavirus related diseases | 北京瑞博开拓医药科技有限公司 | 2023-07-04 | — | — | CN | claimed |
| EP-3238737-B1 | MEANS AND METHODS FOR COUNTERACTING MUSCLE DISORDERS | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2022-04-06 | — | — | EP | claimed |
| US-11274299-B2 | Methods and means for treating DNA repeat instability associated genetic disorders | VICO THERAPEUTICS B.V. (NL) | 2022-03-15 | — | — | US | claimed |
| US-20200140857-A1 | Methods and means for treating DNA repeat instability associated genetic disorders | VICO THERAPEUTICS B.V. (NL) | 2020-05-07 | — | — | US | claimed |
| EP-3265581-B1 | SIMULTANEOUS DETECTION OF OLIGONUCLEOTIDES, A KIT AND A USE RELATED THERETO | AXOLABS GMBH (DE) | 2019-05-01 | — | — | EP | claimed |
| EP-2614827-B1 | Means and methods for counteracting muscle disorders | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2017-06-28 | — | — | EP | claimed |
| EP-2426203-B1 | Agents useful in treating facioscapulohumeral muscular dystrophy | Université de Mons (BE) | 2016-07-13 | — | — | EP | claimed |
| EP-2421971-B1 | OLIGONUCLEOTIDE COMPRISING AN INOSINE FOR TREATING DMD | BIOMARIN TECHNOLOGIES B V (NL) | 2016-07-06 | — | — | EP | claimed |
| EP-2203173-B1 | MEANS AND METHODS FOR COUNTERACTING MUSCLE DISORDERS | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2015-12-23 | — | — | EP | claimed |
| CN-103998458-A | Cell-penetrating peptides having a central hydrophobic domain | MEDICAL RES COUNCIL | 2014-08-20 | — | — | CN | claimed |
| CN-102216462-A | Branched Cationic Lipids for Nucleic Acid Delivery Systems | ENZON PHARMACEUTICALS INC | 2011-10-12 | — | — | CN | claimed |
| CN-102137658-A | Methods, compositions and systems for topical delivery of drugs | SILENSEED LTD | 2011-07-27 | — | — | CN | claimed |
| US-20110092380-A1 | IMPROVED MOLECULAR-BIOLOGICAL PROCESSING EQUIPMENT | FEBIT HOLDING GMBH (DE) | 2011-04-21 | — | — | US | claimed |
| EP-2004156-B1 | COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS | POLYPLUS TRANSFECTION SA (FR) | 2011-01-26 | — | — | EP | claimed |
| CN-101541332-A | Targeted polymeric prodrugs containing multifunctional linkers | ENZON PHARMACEUTICALS INC (US) | 2009-09-23 | — | — | CN | claimed |
| CN-101534643-A | Hindered ester-based biodegradable linkers for oligonucleotide delivery | ENZON PHARMACEUTICALS INC (US) | 2009-09-16 | — | — | CN | claimed |
| CN-101516362-A | Polymeric conjugates containing positively-charged moieties | ENZON PHARMACEUTICALS INC (US) | 2009-08-26 | — | — | CN | claimed |
| CN-101501193-A | Methods and means for treating DNA repeat instability associated genetic disorders | PROSENSA TECHNOLOGIES BV (NL) | 2009-08-05 | — | — | CN | claimed |
| WO-2005048944-A2 | ACTIVATABLE PHOTODYNAMIC THERAPY AGENTS | UNIVERSITY OF PENNSYLVANIA (US) | 2005-06-02 | — | — | WO | claimed |
| WO-2003038122-A2 | ASYMMETRICAL PROBES | FEBIT AG (DE) | 2003-05-08 | — | — | WO | claimed |